These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Update on "open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder". Moroz G; Magni G; Fava M J Clin Psychopharmacol; 2000 Apr; 20(2):285. PubMed ID: 10770481 [No Abstract] [Full Text] [Related]
8. Tolcapone: more than meets the eye? Deleu D; Hanssens Y Am J Health Syst Pharm; 2000 Aug; 57(16):1534. PubMed ID: 10965399 [No Abstract] [Full Text] [Related]
9. Catechol-O-methyltransferase inhibitors in Parkinson's disease. Henry C; Wilson JA Lancet; 1998 Jun; 351(9120):1965-6. PubMed ID: 9654299 [No Abstract] [Full Text] [Related]
11. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy. Borges N Drug Saf; 2003; 26(11):743-7. PubMed ID: 12908845 [TBL] [Abstract][Full Text] [Related]
12. Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor. Iwuagwu CU; Riley D; Bonoma RA Am J Med; 2000 Apr; 108(6):517-8. PubMed ID: 10866587 [No Abstract] [Full Text] [Related]
13. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease. Sabaté M; Bosch A; Pedrós C; Figueras A Ann Pharmacother; 1999 Nov; 33(11):1228-9. PubMed ID: 10573327 [No Abstract] [Full Text] [Related]
14. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone]. Arnold G; Kupsch A Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007 [TBL] [Abstract][Full Text] [Related]
15. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522 [TBL] [Abstract][Full Text] [Related]
16. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Russ H; Müller T; Woitalla D; Rahbar A; Hahn J; Kuhn W Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):719-20. PubMed ID: 10619191 [TBL] [Abstract][Full Text] [Related]